Research Analysts’ Weekly Ratings Updates for Summit Therapeutics (SMMT)

A number of firms have modified their ratings and price targets on shares of Summit Therapeutics (NASDAQ: SMMT) recently:

• 9/9/2026 – Summit Therapeutics was given a new $25.00 price target by Summit Redstone.
• 9/8/2026 – Summit Therapeutics had its “buy” rating reaffirmed by UBS Group AG. They now have a $33.00 price target on the stock.
• 9/5/2026 – Summit Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/3/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 9/1/2026 – Summit Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 8/26/2026 – Summit Therapeutics had its “buy” rating reaffirmed by Guggenheim.
• 8/26/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 8/25/2026 – Summit Therapeutics was given a new $11.90 price target by Summit Redstone.
• 8/25/2026 – Summit Therapeutics was upgraded by Sanford C. Bernstein from “underperform” to “market perform”. They now have a $11.90 price target on the stock, up from $9.80.
• 8/18/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 8/12/2026 – Summit Therapeutics was upgraded by Leerink Partners from “underperform” to “market perform”. They now have a $13.00 price target on the stock, up from $12.00.
• 8/6/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 7/24/2026 – Summit Therapeutics was given a new $15.00 price target by Jefferies Financial Group Inc..
• 7/24/2026 – Summit Therapeutics had its price target lowered by Stifel Nicolaus from $45.00 to $38.00. They now have a “buy” rating on the stock.
• 7/24/2026 – Summit Therapeutics had its price target lowered by Guggenheim from $40.00 to $38.00. They now have a “buy” rating on the stock.
• 7/24/2026 – Summit Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 7/23/2026 – Summit Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 7/18/2026 – Summit Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.

Summit Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for the treatment of cancer. The company’s lead program is ivonescimab, an investigational bispecific antibody designed to combine immune checkpoint inhibition against PD-1 with selective inhibition of vascular endothelial growth factor A (VEGF-A). Summit is evaluating ivonescimab in clinical studies involving patients with non-small cell lung cancer and other solid tumors.

Summit has entered into a licensing and collaboration agreement with Akeso, a biotechnology company that discovered and developed ivonescimab.